MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session - Recent developments in the field of cancer stem cells and implications in the clinical setting
Cancer stem cells have implications in clinical settings. Only a small portion (<1%) of tumor cells can form new tumors, known as tumor initiating cells or cancer stem cells. These cells express specific cell surface markers that can be identified using flow cytometry and fluorescence-activated cell sorting. Targeting cancer stem cells is important for therapy because they are resistant to chemotherapy and radiation. Combination therapies that target cancer stem cell pathways such as Hedgehog and Wnt signaling or aldehyde dehydrogenase activity may be more effective treatments.
Role of cancer stem cells in cancer therapyniper hyd
Cancer is one of the leading cause of death, till to date there is no perfect treatment due to its stem cell relapse which is not responding to conventional therapies like chemo, radio, surgery. so we should target the cancer stem cell with novel targets like nano, and immunotherapies.
New definition and new theory (stem cell-microRNA Theory) of cancer-by dr.ra...Rajkumar Dhaugoda
Lecture notes on New definition and new theory (stem cell-microRNA Theory) of cancer
General concept of cancer
By Dr.Rkdhaugoda
CTGU, YICHANG CHINA-
Visiting Assistant professor ( FROM NEPAL)
2014- MAY-5th
Cancer stem cell theory and evidence from colorecatalKareem Ahmed
This is a presentation of a review article explaining theory of cancer stem cells with evidences from colorectal cancer at a glance. It was presented at Student Research Symposium at Faculty OF Medicine, Assiut University, Assiut, Egypt,
Role of cancer stem cells in cancer therapyniper hyd
Cancer is one of the leading cause of death, till to date there is no perfect treatment due to its stem cell relapse which is not responding to conventional therapies like chemo, radio, surgery. so we should target the cancer stem cell with novel targets like nano, and immunotherapies.
New definition and new theory (stem cell-microRNA Theory) of cancer-by dr.ra...Rajkumar Dhaugoda
Lecture notes on New definition and new theory (stem cell-microRNA Theory) of cancer
General concept of cancer
By Dr.Rkdhaugoda
CTGU, YICHANG CHINA-
Visiting Assistant professor ( FROM NEPAL)
2014- MAY-5th
Cancer stem cell theory and evidence from colorecatalKareem Ahmed
This is a presentation of a review article explaining theory of cancer stem cells with evidences from colorectal cancer at a glance. It was presented at Student Research Symposium at Faculty OF Medicine, Assiut University, Assiut, Egypt,
Cell within a tumor that possess the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor”.
“CSC can thus only be defined experimentally by their ability to recapitulate the generation of a continuously growing tumor”.
History of DICER1 mutation
DICER1 function
Mutated DICER1 – tumorigenic mechanism
Constellation of lesions associated with DICER1
DICER1 IHC
When to test?
Therapeutic options
Transplant in pediatrics in Acute lymphoblastic Luekemia in CR1Dr. Liza Bulsara
to transplant or not to transplant pediatric luekemia in CR1 Has also been a controversial topic . here we give clear recommendation to transplant in difeerent biology group
El 3 de noviembre de 2015, la Fundación Ramón Areces organizó en su sede en Madrid (C/ Vitruvio, 5) una jornada sobre ‘El cáncer como consecuencia del envejecimiento: posibles soluciones’. Coordinado por la investigadora María Vallet Regí, del Departamento de Química Inorgánica y Bioinorgánica de la Universidad Complutense de Madrid, contó con la presencia, entre otros científicos, de Mariano Barbacid, Lodovico Balducci y Theresa Guise.
Cell within a tumor that possess the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor”.
“CSC can thus only be defined experimentally by their ability to recapitulate the generation of a continuously growing tumor”.
History of DICER1 mutation
DICER1 function
Mutated DICER1 – tumorigenic mechanism
Constellation of lesions associated with DICER1
DICER1 IHC
When to test?
Therapeutic options
Transplant in pediatrics in Acute lymphoblastic Luekemia in CR1Dr. Liza Bulsara
to transplant or not to transplant pediatric luekemia in CR1 Has also been a controversial topic . here we give clear recommendation to transplant in difeerent biology group
Transplant in pediatrics in Acute lymphoblastic Luekemia in CR1
Similar to MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session - Recent developments in the field of cancer stem cells and implications in the clinical setting
El 3 de noviembre de 2015, la Fundación Ramón Areces organizó en su sede en Madrid (C/ Vitruvio, 5) una jornada sobre ‘El cáncer como consecuencia del envejecimiento: posibles soluciones’. Coordinado por la investigadora María Vallet Regí, del Departamento de Química Inorgánica y Bioinorgánica de la Universidad Complutense de Madrid, contó con la presencia, entre otros científicos, de Mariano Barbacid, Lodovico Balducci y Theresa Guise.
Updated version of molecular basis, with implied clinical aspect of the molecular basis.
(contents are taken from standard textbook and i dont own the copyright for the content details.)
Justin F. Gainor, MD; Kurt Schalper, MD, PhD; and Edward B. Garon, MD, MS prepared useful Practice Aids pertaining to immunotherapy for this CME/MOC/CC/CNE activity titled, "New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations." For the full presentation, monograph, complete CME/MOC/CC/CNE information, and to apply for credit, please visit us at http://bit.ly/2UJuQBq. CME/MOC/CC/CNE credit will be available until April 25, 2020.
Dr. ihsan edan abdulkareem alsaimary
PROFESSOR IN MEDICAL MICROBIOLOGY AND MOLECULAR IMMUNOLOGY
ihsanalsaimary@gmail.com
mobile : 009647801410838
university of basrah - college of medicine - basrah -IRAQ
Similar to MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session - Recent developments in the field of cancer stem cells and implications in the clinical setting (20)
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session - Recent developments in the field of cancer stem cells and implications in the clinical setting
1. Cancer stem cells: implications in the clinical setting Malcolm Alison; m.alison@qmul.ac.uk 4 th April 2011
10. Hamburger and Salmon 1977, Science The plating efficiency of most 1 0 tumours is <1% PE = macroscopic colonies formed number of tumour cells plated
16. Fluorescence Activation Process (or Immunofluorescence) FITC FITC Antibodies recognize specific molecules in the surface of some cells But not others When the cells are analyzed by flow cytometry the cells expressing the marker for which the antibody is specific will manifest fluorescence. Cells who lack the marker will not manifest fluorescence Antibodies are artificially conjugated to fluorochromes Antibodies FITC FITC FITC FITC
26. The pre-eminence of ALDH as a cancer stem cell marker Responsible for the oxidation (detoxification) of cytotoxic aldehydes to carboxylic acids RCHO + NAD + + H 2 0 RCOOH + NADH + H + : a major cellular defence mechanism
57. A more complex subclonal architecture in ALL Does genetic diversity affect the nature of tumour propagating cells? Yes, the potency, but not the phenotype (CD34 + CD38 -/low CD19 + )